2-(1,3-dioxoisoindolin-2-yl)ethyltriphenylphosphonium bromide | 65273-64-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(1,3-dioxoisoindolin-2-yl)ethyltriphenylphosphonium bromide
• 英文别名: 1-(2-phthalimidoethyl)triphenylphosphonium bromide；(2-phthalimidoethyl)triphenylphosphonium bromide；[2-(1,3-Dioxo-1,3-dihydro 2H-isoindol-2-yl)ethyl](triphenyl)phosphonium bromide；2-(1,3-dioxoisoindol-2-yl)ethyl-triphenylphosphanium;bromide
• CAS: 65273-64-5
• 化学式: Br*C₂₈H₂₃NO₂P
• 分子量: 516.374
• InChiKey: VJTOJTIIIVWWBJ-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  1.28
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(1,3-dioxoisoindolin-2-yl)ethyltriphenylphosphonium bromide 在 palladium on activated charcoal potassium tert-butylate 、 氢气 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 60.0 ℃ 、310.27 kPa 条件下， 反应 4.0h， 生成 2-(3-(1-trityl-1H-imidazol-4-yl)propyl)isoindoline-1,3-dione
  参考文献：
  名称：

  Novel H3 receptor antagonists. Sulfonamide homologs of histamine

  摘要：

  Sulfonamides derived from 4(5)-(omega-aminoalkyl)-1H-imidazoles containing chain lengths of three- to five-carbons were synthesized. Good to moderate H-3 receptor binding affinities were observed for several butyl and pentyl homologs, whereas binding affinities were considerably weaker in the propyl series. Separation of the imidazole ring and the sulfonamide unit by a four- or five-carbon tether afforded potent H-3 receptor antagonists. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(98)00379-5
• 作为产物：
  描述：

  N-(2-溴乙基)邻苯二甲酰亚胺 、 三苯基膦 以 乙腈 为溶剂， 反应 0.25h， 生成 2-(1,3-dioxoisoindolin-2-yl)ethyltriphenylphosphonium bromide
  参考文献：
  名称：

  N-烷基-S- [3-（哌啶-1-基）丙基]异硫脲的合成和评价：高亲和力和人类/大鼠物种选择性组胺H 3受体拮抗剂

  摘要：

  为了寻找新型的咪唑组胺H 3受体（H 3 R）拮抗剂，合成了含有各种环胺的S-烷基-N-烷基异硫脲化合物。其中，四Ñ烷基小号- [3-（哌啶-1-基）丙基]异硫脲18，19，22，和23被发现表现出有效的和选择性ħ 3在体外抗人H [R拮抗活性3 R，但对体外人类H 4 R无活性。此外，三个烷基同系物18 – 20在体内大鼠脑微渗析中显示组胺释放不活跃，表明物种之间拮抗剂亲和力的差异。此外，在计算机对接研究N- [4-（4-氯苯基）丁基] -S- [3-哌啶-1-基）丙基]异硫脲19和一个较短的与人/大鼠H 3 Rs的同系物17时，发现大鼠和人类H 3 Rs的拮抗剂对接腔之间的结构差异可能是由Ala122 / Val122突变引起的。

  DOI：

  10.1016/j.bmcl.2013.09.052

文献信息

• A Novel Class of Orally Active Non-Peptide Bradykinin B₂ Receptor Antagonists. 4. Discovery of Novel Frameworks Mimicking the Active Conformation
  作者：Yoshito Abe、Hiroshi Kayakiri、Shigeki Satoh、Takayuki Inoue、Yuki Sawada、Noriaki Inamura、Masayuki Asano、Ichiro Aramori、Chie Hatori、Hiroe Sawai、Teruo Oku、Hirokazu Tanaka

  DOI：10.1021/jm980330i

  日期：1998.11.1

  a molecular modeling study reported in part 1 of this series, we designed and synthesized a series of sterically constrained analogues by replacing the N-methylamide group with cis-amide-like rigid moieties. We discovered several bioisosteres and chemically proved that the N-methylamide moiety adopts the cis-amide form in the active conformation. Extensive chemical modification led to the identification

  在最近的文章中，我们报道了一系列8-[[2,6-二氯-3- [N-甲基-N-[（E）-（取代）丙烯酰甘氨酰]氨基] ++ +苄基]氧基]的鉴定。 -2-甲基咪唑并[1,2-a]吡啶类作为第一种口服活性非肽缓激肽（BK）B2受体拮抗剂。末端甘氨酸部分和咪唑并[1,2-a]吡啶部分的优化导致了临床候选药物的发现（5，FR173657）。为了完成结构-活性关系（SAR）研究，我们接下来研究了中心苯环上取代基的作用。结果表明2，6-二氯或2，6-二甲基基团可能在调节1-和3-取代基的构象中起重要作用，并且还可能与B2受体的疏水口袋相互作用。此外，根据本系列第1部分中报道的分子建模研究的结果，我们设计并合成了一系列空间受限的类似物，方法是将N-甲基酰胺基团替换为顺式酰胺样刚性部分。我们发现了几个生物等排体，并化学证明了N-甲基酰胺部分以顺式酰胺形式存在于活性构象中。广泛的化学修饰导致鉴定了以吡咯衍生
• Selective preparation of tetrasubstituted fluoroalkenes by fluorine-directed oxetane ring-opening reactions
  作者：Clément Q Fontenelle、Thibault Thierry、Romain Laporte、Emmanuel Pfund、Thierry Lequeux

  DOI：10.3762/bjoc.16.160

  日期：——

  The selective ring-opening reaction of fluoroalkylidene-oxetanes was directed by the presence of the fluorine atom, enabling a two-step access to tetrasubstituted fluoroalkenes with excellent geometry control. Despite its small van der Waals radii electronic, rather than steric influences of the fluorine atom governed the ring-opening reaction with bromide ions, even in the presence of bulky substituents

  氟代亚烷基-氧杂环丁烷的选择性开环反应是通过氟原子的存在来进行的，从而使两步接触四取代的氟代烯烃具有极好的几何形状控制。尽管其范德华半径电子较小，即使存在大的取代基，氟原子的空间影响也并非由空间影响，而是由溴离子控制。
• SUBSTITUTED AMIDE COMPOUND
  申请人：Kawaminami Eiji

  公开号：US20120184521A1

  公开（公告）日：2012-07-19

  A substituted amide compound is useful as an active ingredient of a pharmaceutical composition, in particular a pharmaceutical composition for treating diseases caused by lysophosphatidic acid (LPA). The compound is of a formula: In this formula, A is an optionally substituted aryl, etc.; B is an optionally substituted 5-membered aromatic hetero ring group; X is a single bond or —(CR X1 R X2 ) n —; n is 1, 2, 3, or 4; R X1 and R X2 are hydrogen, etc.; Y 1 to Y 5 are each CR Y or N; each R Y is hydrogen, etc.; R 1 and R 2 are hydrogen, etc.; m is 1, 2, or 3; R 3 is hydrogen, etc.; and R 4 is an optionally substituted lower alkyl, etc.

  一种替代酰胺化合物作为药物组合物的活性成分是有用的，特别是用于治疗由溶血磷脂酸（LPA）引起的疾病的药物组合物。该化合物的化学式如下： 在这个化学式中，A是可选地取代的芳基等；B是可选地取代的5-成员芳香杂环基团；X是单键或—(CR X1 R X2 ) n —；n为1、2、3或4；R X1 和R X2 为氢等；Y 1 到Y 5 分别为CR Y 或N；每个R Y 为氢等；R 1 和R 2 为氢等；m为1、2或3；R 3 为氢等；R 4 为可选地取代的低碳烷基等。
• [EN] DIHYDROBENZOFURAN DERIVATIVES AS INSECTICIDAL COMPOUNDS<br/>[FR] DÉRIVÉS DE DIHYDROBENZOFURANE EN TANT QUE COMPOSÉS INSECTICIDES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2014172871A1

  公开（公告）日：2014-10-30

  The present invention relates to compounds of formula (I) wherein Q is (Q1) or (Q2) G1 is oxygen or sulfur; Y1 is oxygen, sulfur or CH2; Y2, Y3 and Y4 are each independently C-H, C-R5 or nitrogen, wherein no more than one of Y2, Y3 and Y4 is C-R5; Y5 is hydrogen, halogen, C1-C8alkyl, C1-C8haloalkyl or C3-C8cycloalkyl; Y6 is hydrogen, halogen, cyano, C1-C8alkyl, C1-C8haloalkyl or C3-C8cycloalkyl; R1a is hydrogen, C1-C8alkyl, C1-C8alkoxy, C1-C8alkylcarbonyl or C1-C8alkoxycarbonyl; R1b is hydrogen, C1-C8alkyl, C1-C8alkylcarbonyl or C1-C8alkoxycarbonyl; R3 is C1-C8haloalkyl; R4 is aryl or aryl substituted by one to five R10, or heteroaryl or heteroaryl substituted by one to five R10; R6a is hydrogen, cyano, C1-C8alkyl, C1-C8haloalkyl or C3-C8cycloalkyl; R6b is hydrogen, cyano, C1-C8alkyl, C1-C8haloalkyl or C3-C8cycloalkyl; or R6a and R6b together with the carbon atom to which they are attached may form a 3 to 6-membered carbocyclic ring; and R2a, R2b, R and R are as defined in the claims. The invention also relates to methods of controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or molluscicidally effective amount of a compound of formula I.

  本发明涉及式(I)的化合物，其中Q为(Q1)或(Q2)，G1为氧或硫；Y1为氧、硫或CH2；Y2、Y3和Y4分别独立地为C-H、C-R5或氮，其中Y2、Y3和Y4中最多只有一个为C-R5；Y5为氢、卤素、C1-C8烷基、C1-C8卤代烷基或C3-C8环烷基；Y6为氢、卤素、氰基、C1-C8烷基、C1-C8卤代烷基或C3-C8环烷基；R1a为氢、C1-C8烷基、C1-C8烷氧基、C1-C8烷基羰基或C1-C8烷氧羰基；R1b为氢、C1-C8烷基、C1-C8烷基羰基或C1-C8烷氧羰基；R3为C1-C8卤代烷基；R4为芳基或被1至5个R10取代的芳基，或杂环芳基或被1至5个R10取代的杂环芳基；R6a为氢、氰基、C1-C8烷基、C1-C8卤代烷基或C3-C8环烷基；R6b为氢、氰基、C1-C8烷基、C1-C8卤代烷基或C3-C8环烷基；或R6a和R6b与它们连接的碳原子一起可以形成3至6成员的碳环；R2a、R2b、R和R如权利要求中所定义。本发明还涉及一种控制昆虫、螨虫、线虫或软体动物的方法，包括向害虫、害虫的生境或易受害虫侵袭的植物施加式I化合物的杀虫、杀螨、杀线虫或杀软体动物有效量。
• Heterocyclic compounds as bradykinin antagonists
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06344462B1

  公开（公告）日：2002-02-05

  This invention relates to a compound of the formula: wherein A1 is lower alkylene, R1 is substituted quinolyl, etc., R2 is hydrogen, halogen or lower alkyl, R3 is halogen or lower alkyl, and R4 is a group of the formula: —Q—A2—R5, etc.,  in which R5 is amino, acylamino, etc., A2 is lower alkylene or a single bond, and Q is a group of the formula:  and pharmaceutically acceptable salts thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to methods of using the same therapeutically in the prevention and/or the treatment of bradykinin or its analogues mediated diseases in human being or animals.

  这项发明涉及一种化合物，其化学式为：其中A1是较低的烷基烯，R1是取代的喹啉基等，R2是氢、卤素或较低的烷基，R3是卤素或较低的烷基，R4是式的一个基团：—Q—A2—R5等，其中R5是氨基、酰胺基等，A2是较低的烷基烯或一个单键，Q是式的一个基团：，以及其在药学上可接受的盐，制备方法，包含相同化合物的药物组成，以及在治疗人类或动物的布雷金激肽或其类似物介导的疾病的预防和/或治疗中使用的方法。